https://doi.org/10.5281/zenodo.15826884

NEXUS KNOWLEDGE PUBLICATION

https://nknpub.com/index.php/1

Modern Pharmaceutics

ISBN Number- 978-81-985724-8-6

Chapter- 1



PREFORMULATION AND PHARMACEUTICAL DISPERSION SYSTEMS

SMITA WASNIK
Assistant professor
Valmik Naik College of Pharmacy, Talwadi Tq Kannad Dist,
Chhatrapati Sambhaji Nagar (Aurangabad), Maharashtra, Pin - 431003
Email: smitawasnik111@gmail.com

DR. TUSAR BAJPAI
Assistant Professor, Department Of Chemistry, Hariom Saraswati P. G. College Dhanauri,
Haridwar, Uttarakhand, PIN - 247667
Email: tusar.bajpai@yahoo.com

DR. SYED AHMED IIZHAR
Professor, Department of Pharmaceutics
Sultan Ul Uloom College of Pharmacy, Hyderabad
Email: iizharahmedsyed@gmail.com

DR. PRANABESH SIKDAR
Professor, Royal School of Pharmacy, The Assam Royal Global University, Betkuchi,
Opp. Tirupati Balaji Temple, NH 37,
Guwahati - 781035, Assam, India
Email: pranawesh@rediffmail.com

MR. HARISH SHARMA
Department of Pharmaceutics
Assistant professor
Shri Ram College of pharmacy, Banmore,
Near Gwalior, 476444
Email: hs9277587@gmail.com

Published By – Nexus Knowledge Publication

(Imprint of AKT Multitask Consultancy)

Bilaspur, Chhattisgarh, India, 495006

www.aktmultitask.com

DOI 10.5281/zenodo.15826883. https://doi.org/10.5281/zenodo.15826884

Chapter - 1

PREFORMULATION AND PHARMACEUTICAL DISPERSION SYSTEMS

SMITA WASNIK
Assistant professor
Valmik Naik College of Pharmacy, Talwadi Tq Kannad Dist,
Chhatrapati Sambhaji Nagar (Aurangabad), Maharashtra, Pin - 431003
Email: smitawasnik111@gmail.com

DR. TUSAR BAJPAI
Assistant Professor, Department Of
Chemistry, Hariom Saraswati P. G. College Dhanauri,
Haridwar, Uttarakhand, PIN - 247667
Email: tusar.bajpai@yahoo.com

DR. SYED AHMED IIZHAR
Professor, Department of Pharmaceutics
Sultan Ul Uloom College of Pharmacy, Hyderabad
Email: iizharahmedsyed@gmail.com

DR. PRANABESH SIKDAR
Professor, Royal School of Pharmacy, The Assam Royal Global University, Betkuchi,
Opp. Tirupati Balaji Temple, NH 37, Guwahati - 781035, Assam, India
Email: pranawesh@rediffmail.com

MR. HARISH SHARMA
Department of Pharmaceutics
Assistant professor
Shri Ram College of pharmacy, Banmore, Near Gwalior, 476444
Email: hs9277587@gmail.com

A key stage in the creation of pharmaceutical dosage forms is Preformulation, which entails researching the physicochemical characteristics of a medication ingredient and how they affect the finished product [1]. Understanding the behaviour of the medication and its interactions with excipients is crucial for creating formulations that are stable, safe, and effective.

Preformulation

Characterising the active pharmaceutical ingredient (API) prior to its combination with excipients to create the final dosage form is known as Preformulation. This procedure aids in choosing the best formulation strategy based on the characteristics of the medication.

The key components of Preformulation include:

- **Drug Identification**: Making sure that the medicine is appropriately recognised and that its purity and potency are evaluated are also important steps.
- **Solubility and Dissolution Rate**: In order for a medicine to be bioavailable, its solubility is of the utmost importance. The evaluation of the drug's solubility in various solvents (water, organic solvents, etc.) and the identification of potential issues in dissolving rates are both facilitated by preformulation.
- **Stability Testing**: Through the use of stability studies, preformulation is able to determine how environmental conditions (such as temperature, humidity, and light) influence the stability of the active pharmaceutical ingredient (API) over time.
- **Physical Characteristics**: This includes the drug's particle size, morphology, and crystal shape, all of which have an impact on the drug's stability, bioavailability, and rate of dissolution.
- **Melting Point and Polymorphism**: The solubility and bioavailability of the medication are both affected by these features. Some polymorphic variants can have pharmacokinetic and pharmacodynamic features that are distinct from one another.
- **pH and pKa**: There is a correlation between the pH of the environment and the ionisation of the medication. The pH range that is ideal for drug stability and solubility can be determined with the assistance of preformulation experiments.
- **Permeability**: Evaluation of the drug's ability to pass through biological membranes (intestinal permeability) is part of the preformulation process. This evaluation is done in order to forecast the drug's absorption.

The design of the final dosage form and the selection of appropriate excipients are guided by these preformulation studies.

Pharmaceutical Dispersion Systems

Pharmaceutical dispersion systems are formulations where the medicine is either a liquid dispersed in another liquid or a solid scattered in a continuous medium [2]. For medications with low bioavailability or solubility, these systems are crucial. The objective is to improve the drug's absorption and dissolution in order to increase its therapeutic effectiveness. Pharmaceutical dispersion systems come in the following primary varieties:

a. Suspensions (Solid-Liquid Dispersions)

The medication is distributed as solid particles within a liquid medium in suspensions. When a medication has poor water solubility, these systems are frequently employed.

- **Characteristics**: It is important to ensure that the solid particles in a suspension are fine and stable in order to achieve equal dispersion. The rate of dissolution and, consequently, the bioavailability are both influenced by the particle size.
- **Stabilization**: Stabilising suspensions is necessary in order to not only prevent settling but also to ensure consistency. The utilisation of flocculating agents, viscosity enhancers, or surfactants are all viable options for accomplishing this endeavour.
- **Examples**: Suspensions that are administered orally (such as antibiotics like amoxicillin), as well as injectable suspensions (such as depot formulations).

b. Emulsions (Liquid-Liquid Dispersions)

Systems known as emulsions occur when one liquid disperses in another that is immiscible, usually as droplets. These are employed to provide medications that are soluble in oils or fats but poorly soluble in water.

- **Types**:
    - **Oil-in-water (O/W)**: Intravenous lipid emulsions are an example of a situation in which the oil is spread in the water phase.
    - **Water-in-oil (W/O)**: When applied topically, such as in ointments and creams, water droplets are disseminated throughout the oil phase.

- **Stabilization**: For the purpose of stabilising the dispersed phase and preventing phase separation, emulsions require the presence of emulsifying agents. Certain emulsifiers, such as lecithin, polysorbates, and cetyl alcohol, are frequently used.
- **Examples**: Parenteral nutrition, topical emulsions, and oral emulsions.

c. Nanosuspensions

Submicron dispersions of poorly soluble medications in a liquid medium are known as nanosuspensions [3]. Usually, the drug particles range in size from 200 nm to 1 μm. By expanding the surface area, nanosuspensions accelerate the pace at which poorly soluble medications dissolve.



Figure 1.1: Preparation Of Nanosuspensions

- **Manufacturing Methods**: Techniques such as solvent evaporation, media milling, and high-pressure homogenisation are used to create nanosuspensions.
- **Advantages**: They can be utilised for parenteral and oral medication delivery, and they increase drug solubility and bioavailability.
- **Examples**: Anticancer drugs, antifungal agents.

a. Liposomes and Nanoparticles

Both hydrophilic and lipophilic medications can be encapsulated in liposomes, which are spherical vesicles made of lipid bilayers [4]. Solid, submicron-sized particles, known as nanoparticles, can be formed from a variety of substances, such as metals, polymers, or lipids.

DOI 10.5281/zenodo.15826883. https://doi.org/10.5281/zenodo.15826884

- **Liposomes**: They are employed to improve the way medications are delivered to particular locations (e.g., anticancer medicines targeting tumour cells).
- **Nanoparticles**: Especially in fields like gene therapy and anticancer drug delivery, they enhance drug solubility, stability, and targeted distribution.

b. Hydrogels

Three-dimensional networks of polymers called hydrogels are capable of absorbing a lot of water without losing their structural integrity. They are employed in the creation of medication delivery systems with controlled release.

Figure 1.2: Hydrogel Drugs

- **Mechanism**: The release rate of the drug is controlled by the diffusion of the drug through the hydrogel matrix [5]. Drugs are either entrapped or covalently bound within the hydrogel matrix.
- **Applications**: Wound healing, ocular drug delivery, and controlled release of proteins or peptides.

Formulation Considerations

When formulating pharmaceutical dispersion systems, several factors must be considered:

- **Viscosity**: The drug's release rate and the ease with which it can be administered are both impacted by the viscosity of the dispersion. It is necessary, for instance, for suspensions or emulsions intended for oral use to have a viscosity that is appropriate in order to avoid blockage or difficulty in swallowing.

- **Particle Size**: Smaller particle sizes result in an increase in surface area, which in turn leads to an increase in the rate of dissolution and utilisation. Having particles that are too small, on the other hand, could cause stability issues.
- **Stability**: When it comes to pharmaceutical dispersions, stability is essential throughout time. It is necessary to avoid phase separation, precipitation, and changes in particle size in order to accomplish this. Excipients, which include stabilisers, surfactants, and antioxidants, can be chosen in such a way as to guarantee the product's stability.
- **Release Profile**: In order to meet the therapeutic requirements, the rate at which the medicine is released from the dispersion system must be appropriate. In order to ensure that the drug is released gradually over a longer period of time, controlled or sustained-release formulations are developed.

1.1.PREFORMULATION CONCEPTS

The first stage of the drug development process, known as preformulation, entails examining the physicochemical characteristics of a drug substance (also known as an active pharmaceutical ingredient, or API) to determine how it will behave in a formulation and to help choose the excipients for the finished dosage form [6]. The stability, bioavailability, and general therapeutic efficacy of the medication depend heavily on this phase. Prior to entering the formulation development phase, preformulation aids in identifying the best formulation approach.

Preformulation encompasses a wide range of scientific investigations and testing that shed light on the API's stability, solubility, and compatibility with excipients under various circumstances [7]. The objective is to specify the drug's properties that will direct the creation of the finished dosage form.

Here are the key components and concepts in Preformulation:

- **Identification of the Drug**

Finding and verifying the drug's identity is the first stage in preformulation. This entails verifying that the medication is appropriately synthesised or derived from natural sources and evaluating its purity.

- Identification Tests: The identification of the drug's molecular structure and the verification of its legitimacy are typically accomplished through the utilisation of techniques such as infrared spectroscopy (IR), nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry (MS).
- Purity Testing: For the sake of the drug's efficacy and safety, it is absolutely necessary to check that it is free of any contaminants. The analysis of purity can be accomplished by the utilisation of methods such as high-performance liquid chromatography (HPLC).

➢ **Solubility and Dissolution Rate**

One of the most crucial factors affecting a drug's bioavailability is its solubility. Preformulation studies involve assessing the drug's solubility in various solvents (such as water, organic solvents, and physiological fluids) at different pH levels.

- **Solubility Studies:** Determining the formulation strategy is aided by knowledge about the drug's solubility in various solvents and pH levels [8]. For example, the use of solubility-enhancing methods (such as solid dispersions, co-solvents, or surfactants) may be necessary if the medicine has low water solubility.
- **Dissolution Rate:** This describes the rate at which a medication dissolves in a solvent. Better absorption may result from a higher rate of dissolution. For oral preparations, where the medicine must dissolve rapidly in the gastrointestinal tract in order to be absorbed, it is particularly crucial.

➢ **Stability Testing**

The purpose of stability testing is to determine how environmental elements such as light, humidity, and temperature impact the drug's and its formulation's long-term stability.

- **Shelf Life:** It is possible to make an accurate prediction of the shelf life of the final product and the conditions under which it should be stored by conducting preformulation stability testing.
- **Factors Influencing Stability:** In addition to the presence of light, the drug's stability can be affected by a variety of parameters, including pH, temperature, and moisture content. The degradation of the active pharmaceutical ingredient (API) can result in a modification of the formulation's appearance, the development of harmful by-products, or a loss of efficacy.

- **Types of Stability Studies:** Long-term stability can be predicted through the use of accelerated stability tests, which are conducted at greater temperatures and humidity levels. For the purpose of determining the shelf life, real-time stability studies are carried out in typical environments for storage.

➢ **Physical Characteristics**

When creating the right formulation and dosage form, the API's physical characteristics are crucial [9]. These consist of:

- **Particle Size and Distribution:** The stability, bioavailability, and rate of dissolution are all impacted by the size and dispersion of the drug particles. Because fine particles have more surface area, dissolving may be enhanced. To guarantee homogeneity, the particle size distribution can be managed by the use of milling processes.
- **Morphology:** Drug stability and dissolution are also influenced by the form and structure of the drug particles, such as their crystal, amorphous, or polymorphic forms. Although they may be less stable, amorphous medications often dissolve more quickly than crystalline ones.
- **Polymorphism:** Certain medications can exist in several crystalline forms, or polymorphs, each with unique characteristics. The most stable polymorph, together with its solubility and bioavailability properties, can be determined by preformulation research.
- **Melting Point:** A drug's stability and applicability for various formulations are determined in part by its melting point (a greater melting point may be beneficial for solid forms, for example).

➢ **pH and pKa**

The drug's solubility, stability, and bioavailability can all be strongly impacted by a formulation's pH.

- **pH-Dependent Solubility:** Certain medications dissolve better under alkaline or acidic conditions. Formulators can choose the ideal pH range for the drug's formulation by testing solubility over a variety of pH values.

- **pKa:** The pH at which a medication exists in an ionised or neutral state is determined by its pKa value. The drug's permeability and solubility are impacted by the ionisation, which also affects how well the body absorbs it.

➢ **Permeability**

Oral bioavailability is mostly dependent on a drug's permeability, which is its capacity to flow across biological membranes like the intestinal barrier.

- In Vitro Permeability Studies: To assess a drug's ease of passage through the intestinal barrier, methods such using Caco-2 cells—a human intestinal cell line—are frequently employed.
- Molecular Size: Larger molecular weight drugs may have reduced permeability, necessitating formulation or medication changes (e.g., usage of nanoparticle formulations or permeation enhancers).

➢ **Compatibility with Excipients**

An essential component of preformulation is the way the API interacts with excipients, which are inert substances included in formulations [10]. The drug's performance, solubility, and stability may all be impacted by these interactions.

- **Excipient Selection:** Excipients are chosen based on their function in the formulation (e.g., binders, fillers, preservatives, stabilisers, and lubricants) and compatibility with the API. Excipients that do not react with the API or change its functionality can be found with the use of preformulation research.
- **Compatibility Studies:** The physical and chemical interactions between the medicine and excipients under various conditions (such as temperature, humidity, and storage period) are frequently tested in these investigations.

➢ **Toxicity and Safety Considerations**

To make sure the medication doesn't have any negative effects, toxicity studies are a crucial component of Preformulation [11]. Among the safety information acquired during preformulation are:

- Acute Toxicity Studies: These investigations aid in figuring out the drug's lethal dose (LD50) and the likelihood of acute adverse responses.

- Chronic Toxicity Studies: Preformulation for medications intended for long-term use includes research to evaluate the risk of chronic toxicity, including mutagenicity and organ toxicity.

➢ **Excipients and Formulation Design**

The choice of excipients, or inactive substances, and the design of the finished dosage form—such as tablets, capsules, suspensions, creams, etc.—are decided upon based on the findings of the preformulation studies.

- Formulation Strategies: Techniques such as solid dispersions, cyclodextrin inclusion complexes, or liposomal formulations may be investigated in order to improve the solubility and bioavailability of pharmaceuticals that have a low solubility.
- Controlled-Release Formulations: In order to manage the release of the medicine over a period of time, preformulation studies are helpful in determining the proper excipients and technologies. Some examples of these technologies are matrix tablets, osmotic pumps, and film coatings.

➢ **Analytical Methods and Quality Control**

During preformulation, it is essential to establish analytical methods to test the drug's identity, purity, and quality. These methods include:

- Chromatography (HPLC, GC)
- Spectroscopy (UV, IR, NMR, MS)
- Stability Testing (accelerated and real-time)

Because it offers a scientific foundation for creating an ideal formulation, preformulation is an essential stage in the drug development process [12] . It entails comprehending the active pharmaceutical ingredient's (API) physical, chemical, and biological characteristics as well as how it interacts with excipients and the human body. Preformulation guarantees that the finished pharmaceutical product will be safe, effective, and dependable for patients by taking into account aspects like solubility, stability, and compatibility.

1.1.1. Drug-Excipient Interactions (Methods and Evaluation)

Potential interactions between the active pharmaceutical ingredient (API) and the excipients (inactive substances) utilised in pharmaceutical product formulation are referred to as drug-excipient interactions [13]. The drug product's stability, bioavailability, safety, and general efficacy may all be impacted by these interactions. A crucial element in the preformulation stage is identifying and assessing these interactions to make sure the medication formulation is stable, safe, and effective for patients.

Types of Drug-Excipient Interactions

a. Physical Interactions:

When the excipient affects the physical characteristics of the API, physical interactions take place. Changes in the drug's solubility, particle size, or crystallinity may arise from these interactions, which may then have an impact on the drug's bioavailability and rate of dissolution. To increase a crystalline drug's solubility, for example, an excipient may transform it into an amorphous form. On the other hand, the interaction may also cause an amorphous medication to crystallise, which would decrease its solubility [14].

b. Chemical Interactions:

molecular interactions occur when the medicine and excipient react, changing the API's molecular structure. Hydrolysis, oxidation, and other degrading processes may fall under this category. For instance, some excipients may hasten the API's deterioration, resulting in decreased stability and effectiveness. Additionally, excipients may combine with the medicine to generate salts, which may alter the drug's solubility or pharmacokinetics, including absorption.

c. Thermodynamic Interactions:

Changes in thermodynamic qualities, including melting points or solubility, are referred to as thermodynamic interactions [15]. The drug's melting point, which affects its solubility, can be influenced by excipients. For instance, an excipient may change the drug's dissolving properties by lowering its melting point. Furthermore, some excipients, such cyclodextrins, which are frequently used for medications that are poorly soluble in water, may form inclusion complexes with the drug, increasing its solubility.

d. Kinetic Interactions:

Changes in the rate of medication solubility, absorption, or degradation are referred to as kinetic interactions. Certain excipients may change the drug's rate of dissolution, which could impact its bioavailability [16]. Another illustration of kinetic interactions is the API's accelerated degradation when excipients are present. Such modifications could have an impact on the drug's efficacy, possibly resulting in a decrease in potency or the production of hazardous breakdown products.

Methods to Evaluate Drug-Excipient Interactions

A variety of methods must be used when evaluating drug-excipient interactions in order to spot any possible formulation problems [17]. By evaluating the drug's and excipients' chemical and physical compatibility, these techniques can guarantee the stability and efficacy of the finished formulation.

a. Preformulation Studies:

Prior to formulation, preformulation studies are crucial for assessing the drug's compatibility with different excipients [18]. The solubility, stability, and physical characteristics of the medicine when combined with various excipients are usually evaluated in these investigations. To find out how the excipients affect the drug's solubility at various pH levels, solubility tests are carried out. Stability studies, which include testing conducted in a range of temperature, humidity, and light settings, assess whether the medicine deteriorates over time when mixed with excipients [19].

b. Spectroscopic Techniques:

Spectroscopic techniques are frequently employed to identify chemical interactions between excipients and drugs. A chemical interaction may be indicated by changes in the drug's functional groups, such as the emergence of new peaks or shifts in preexisting peaks, which can be detected using Fourier Transform Infrared Spectroscopy (FTIR). By identifying changes in the molecular environment, Nuclear Magnetic Resonance (NMR) spectroscopy sheds light on how the drug's molecules change when combined with excipients. By analysing variations in the drug's absorbance properties, ultraviolet-visible (UV-Vis) spectroscopy can be used to find interactions that might affect the stability or release of the medicine.

c. Chromatographic Techniques:

Chromatographic techniques, such High-Performance Liquid Chromatography (HPLC), are useful for identifying products of chemical degradation and guaranteeing the stability of the medication when excipients are present.



Figure 1.3: Chromatographic Techniques

A drug-excipient mixture's constituents can be separated and quantified using HPLC, enabling the identification of any newly formed or broken-down molecules. When it comes to volatile chemicals, gas chromatography (GC) can identify potential degradation products or interactions that might change the stability of the medication.

d. Differential Scanning Calorimetry (DSC):

A drug-excipient mixture's melting point, crystallisation, and other phase transitions are among the thermal characteristics that DSC measures. DSC can identify interactions that alter the drug's stability, melting behaviour, or crystallinity by comparing the thermal profiles of the drug by itself and in combination with excipients [20]. Changes in the heat flow or a shift in the melting point may be signs of important interactions that could impact the formulation's functionality.

e. X-ray Powder Diffraction (XRD):

X-ray powder diffraction (XRD) is used to analyse the drug's and excipients' crystallinity. When the medication is combined with excipients, changes in the diffraction patterns may show the emergence of new crystalline phases, co-crystals, or amorphous forms. Since these modifications may impact the drug's rate of solubility and bioavailability, XRD is a crucial method for spotting possible interactions.

f. Isothermal Calorimetry:

At a constant temperature, isothermal calorimetry calculates the amount of heat that is absorbed or released during a chemical reaction. By identifying exothermic or endothermic reactions between the drug and excipients, this method can reveal the type of interactions that may occur. A shift in the heat flow, for instance, could indicate that an interaction has resulted in the creation of a new solid phase or a chemical bond.

g. Stability Studies:

To evaluate the behaviour of the drug-excipient mixture under various storage circumstances, stability tests are carried out. Researchers can forecast the formulation's long-term stability by subjecting it to high temperatures and humidity during accelerated stability testing, which speeds up any possible chemical reactions. To keep an eye on the product's stability throughout its planned shelf life, real-time stability testing is carried out under typical storage settings [24].

h. In Vitro Release Testing:

Excipients' effects on the drug's release from the formulation are assessed using in vitro release testing, such as dissolution testing. Formulators can ascertain whether excipients change the rate of dissolution, which in turn impacts bioavailability, by testing the drug-excipient mixture in a variety of dissolution media. This test guarantees that the formulation satisfies therapeutic requirements and aids in predicting the drug's behaviour in vivo.

Assessment of Drug-Excipient Interactions

It is necessary to assess the possible effects of drug-excipient interactions on the medication's efficacy and safety after they have been discovered. Several important issues are the focus of this assessment:

a. Impact on Bioavailability

Bioavailability can be strongly impacted by drug-excipient interactions that alter permeability, solubility, or dissolution rate. For example, an excipient can either increase or decrease the amount of medicine taken into the bloodstream if it changes the solubility of the API. Addressing these interactions early in the formulation process is essential since poor bioavailability might lead to a diminished therapeutic impact.

b. Impact on Stability

The stability of the formulation may be impacted by chemical interactions between the medication and excipients that cause degradation, such as oxidation, hydrolysis, or thermal degradation. Impurities or degradation products may occur as a result of reduced stability, thereby reducing the drug's potency or producing harmful side effects. Under typical storage conditions, formulators must make sure that excipients don't encourage deterioration.

c. Toxicity

The medicine's therapeutic margin may be lowered or harmful byproducts may result from interactions between the drug and certain excipients. For instance, an excipient may change the pharmacodynamics of the API in a way that has negative consequences or promote the production of hazardous degradation products. To prevent any negative effects, it is crucial to evaluate the drug-excipient combination's safety profile.

d. Effect on Therapeutic Effectiveness

The therapeutic efficacy of the medication may be impacted by any interaction that modifies its pharmacokinetic characteristics, including its absorption, distribution, metabolism, or elimination. The efficacy of the API to produce the intended therapeutic effect may be improved or hampered by excipients that affect the rate of breakdown or absorption. For the formulation to be successful, it is imperative that excipients do not impede the drug's intended effect.

One of the most important aspects of pharmaceutical development is assessing drug-excipient interactions. Formulators can create therapeutic products that are stable, safe, and effective for patients by knowing how excipients interact with the active pharmaceutical ingredient (API). Potential interactions can be found early in the formulation process by using sophisticated techniques like spectroscopy, chromatography, calorimetry, and stability studies. This lowers the chance of formulation failures and guarantees that the finished product has the appropriate pharmacological and safety profiles.

1.2. STABILITY STUDIES

Because they offer vital information on how a therapeutic product behaves over time under varied environmental conditions, stability studies are crucial in the development of pharmaceutical goods. These investigations evaluate a formulation's overall efficacy, physical

alterations, chemical stability, and patterns of degradation over time. Making that the medication product maintains its intended potency, safety, and efficacy over time is the main goal of stability testing.

Purpose of Stability Studies

Stability studies are conducted primarily to assess the drug product's performance over time under various storage circumstances. Stability testing specifically aids in:

- Determine Shelf Life: When the drug is stored according to specified guidelines, it helps determine how long it will remain fully potent, effective, and safe.
- Evaluate Storage Conditions: Within the context of medicine formulation, stability studies investigate the ways in which environmental elements including temperature, humidity, light, and oxygen exposure influence the treatment. The information that you have provided is essential for identifying the conditions that are most suitable for storage and packaging.
- Understand Degradation Pathways: The purpose of these investigations is to identify any degradation products that may emerge over time and to determine the potential influence that these products may have on the efficacy or safety of the medicine.
- Ensure Regulatory Compliance: For the purpose of ensuring that the drug product satisfies the essential standards for marketing approval, regulatory bodies such as the FDA and EMA need stability studies to be conducted within a certain time frame.

Types of Stability Studies

Stability studies can be categorized based on different factors such as time duration, conditions tested, and the type of product involved. The main types include:

Accelerated Stability Studies

To hasten the degradation process, these investigations are carried out at high temperatures and humidity conditions. By subjecting the medication to stressful situations for a shorter amount of time, the long-term stability of the drug is to be predicted. In a standard accelerated stability trial, for instance, the medication might be kept for six months at 40°C and 75% relative

humidity. Long-term stability testing is still necessary, although these trials offer preliminary information on the drug's possible shelf life.

- **Objective:** Predict long-term stability and degradation patterns in a shorter time frame.
- **Conditions:** Usually conducted at 40°C ± 2°C and 75% RH (Relative Humidity).
- **Duration:** Typically, 6 months.

Long-Term Stability Studies

Studies of long-term stability are conducted in settings that are similar to real storage settings. The product is kept at the proper humidity levels and at the recommended storage temperature, such as room temperature or 25°C . The results of these studies, which usually span one to five years, offer more trustworthy information regarding the drug's long-term durability.

- **Objective:** Determine the real-time deterioration and stability of the substance under the conditions of traditional storage.
- **Conditions:** A typical storage temperature of 25°C ± 2°C and a relative humidity of 60% is standard.
- **Duration:** Between one and five years, depending on the criteria of the regulatory body.

Intermediate Stability Studies

These experiments are carried out under circumstances that fall somewhere between those of long-term and rapid testing. The goal is to keep an eye on the medication's stability in mild environmental circumstances. Temperatures of 30°C ± 2°C and 65% relative humidity are normal. These studies can aid in bridging the gap between long-term and rapid research.

- **Objective:** Assess the drug's stability in moderate conditions to complement long-term studies.
- **Conditions:** Typically, 30°C ± 2°C and 65% RH.
- **Duration:** In most cases, between six months and one year.

Stress Testing

Stress testing is exposing the drug formulation to harsh circumstances, including exposure to light, humidity, and extremely high or low temperatures. The purpose of this kind of testing is to determine the drug's inherent stability and to find any degradation products that might appear in extreme circumstances. Stress testing aids in identifying the active pharmaceutical ingredient's (API) stability and degradation routes under harsh environmental conditions.

- **Objective:** Identify potential degradation products and determine the inherent stability of the drug.
- **Conditions:** Extreme temperature, light, and humidity exposure.
- **Duration:** Varies based on the purpose of the test.

Parameters Tested in Stability Studies

Stability studies focus on evaluating several key parameters of the drug formulation to determine its quality over time:

- **Physical Appearance**

Stability studies track the drug formulation's physical attributes, including colour, texture, and shape. Problems like phase separation, crystallisation, or disintegration may be indicated by changes in appearance. For example, a tablet may get fractures or discolouration, which could be signs of instability.

- **pH and Viscosity**

One crucial stability factor for liquid formulations, including suspensions and solutions, is pH. The stability and solubility of the medication may be impacted by notable pH variations. To make that the medication keeps its desired consistency and quality over time, the viscosity of some formulations (such as suspensions or gels) is also tracked.

- **Active Ingredient Content (Potency)**

Monitoring the potency of the API over time is one of the most important stability tests. High-performance liquid chromatography (HPLC) or other analytical techniques are used for potency testing to make sure the active ingredient's concentration stays within a reasonable

range. A gradual decrease in potency suggests that the medication is deteriorating and that its effectiveness may be jeopardised.

- **Degradation Products**

The chemical byproducts known as degradation products are created when a medicine degrades as a result of exposure to environmental elements like heat, light, and moisture. Because they may not only lessen the drug's therapeutic effectiveness but also present safety issues, these by-products are constantly watched throughout stability tests. Degradation products are identified and quantified by specific assays.

- **Dissolution Rate**

Stability testing measures the rate at which solid oral dosage forms, like tablets or capsules, dissolve. A shift in the dissolving properties over time may be a sign of modifications to the drug's effectiveness and bioavailability. The formulation's ability to release the API consistently throughout time is ensured via dissolution tests.

- **Microbial Contamination**

A major worry is microbial contamination, especially for formulations that are liquid or semi-solid. Stability studies use microbial growth assays to evaluate the formulation's microbiological quality. The safety and effectiveness of the medication may be jeopardised by any microbial contamination.

- **Container-Closure Integrity**

The integrity of the container-closure system is also tested as part of stability tests since it can influence how the medicine is exposed to air and moisture. The formulation may deteriorate or pollutants may enter as a result of a damaged container system.

- **Data Analysis and Shelf-Life Prediction**

The shelf life and suggested storage conditions for the medication product are ascertained by analysing the stability data that has been gathered. The expiration date and the product's ability to maintain the necessary potency and safety over time are determined using the degradation data. The Arrhenius equation, which is frequently applied in accelerated stability tests, aids in

determining the drug's shelf life by predicting the rate of chemical reactions (such as deterioration) at various temperatures.

- **Statistical Analysis**

To identify trends in degradation and make sure that any changes are statistically significant, data from stability studies are statistically analysed. This aids in determining the product's expiration date and predicting its long-term stability.

- **Regulatory Guidelines**

Regulations from organisations like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) must be followed by stability studies. In order to guarantee that pharmaceutical businesses produce products that satisfy safety, efficacy, and quality criteria, these recommendations provide the necessary conditions, duration, and parameters for stability testing.

Regulatory Requirements for Stability Testing

In order to approve a medicine, regulatory bodies including the FDA, EMA, and ICH (International Council for Harmonisation) need stability data. The methodologies for expedited, long-term, and intermediate stability studies are outlined in the internationally recognised ICH recommendations (Q1A-R2) for pharmaceutical stability testing. When submitting a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) for approval, regulatory bodies must receive the data produced by stability studies. A vital component of the pharmaceutical development process, stability studies offer the information required to guarantee that a medication product is safe, effective, and of the highest calibre for the duration of its shelf life. These investigations aid in discovering degradation products, figuring out when a drug expires, and assessing how environmental conditions affect a product's performance. Stability studies, which involve extensive testing under many situations, guarantee that pharmaceutical goods fulfil regulatory standards and offer patients consistent therapeutic advantages.

1.2.1. Kinetics of Stability (Zero and First-Order Reactions)

Kinetics of stability entails comprehending how a medication product's stability varies over time and in different environmental settings. A common assumption in stability studies is that

the active pharmaceutical ingredient (API) would degrade according to a particular reaction order, usually either zero-order or first-order processes. Predicting the shelf life and rate of deterioration of pharmaceutical items requires an understanding of these reaction processes.

➢ **Zero-Order Kinetics**

The pace at which the medicine degrades in zero-order reactions is unaffected by the active ingredient's concentration. This indicates that no matter how much of the medicine is still in the formulation, the amount that breaks down over time stays constant.

- **Mathematical Expression:** The general equation for zero-order kinetics is:

$$C_t = C_0 - kt$$

Where:

  - Ct is the concentration of the drug at time ttt.
  - C0 is the initial concentration of the drug.
  - k is the rate constant (usually given in units of concentration/time).
  - t is the time elapsed.

The drug's concentration falls linearly with time in zero-order kinetics. This paradigm is frequently used for dosage forms where the medicine is intended to release or degrade at a consistent rate over time, such as controlled-release or sustained-release drugs.

- **Half-Life for Zero-Order Reaction:** The half-life in zero-order reactions is given by:

$$t_{1/2} = \frac{C_0}{2k}$$

As seen from this equation, the half-life is **dependent on the initial concentration**. This is different from first-order reactions, where half-life is independent of concentration.

➢ **First-Order Kinetics**

In **first-order reactions**, The drug's rate of breakdown is closely correlated with its concentration. This implies that as the drug's concentration falls over time, so does the rate of breakdown.

- **Mathematical Expression:** The general equation for first-order kinetics is:

$$\ln(C_t) = \ln(C_0) - kt$$

Where:

  - Ct is the concentration of the drug at time t.
  - C0 is the initial concentration of the drug.
  - k is the rate constant (given in units of 1/time).
  - t is the time elapsed.

In this instance, a higher starting concentration leads to a longer degradation period because the drug's concentration decreases exponentially over time. For medications that break down logarithmically over time, like simple drug solutions or goods with a somewhat unstable API, this model is frequently used.

- **Half-Life for First-Order Reaction:** The half-life in first-order reactions is constant and independent of the initial concentration:

$$t_{1/2} = \frac{0.693}{k}$$

As this formula shows, the half-life is constant and remains the same regardless of how much drug is initially present, making this a characteristic feature of first-order degradation.

➢ **Application of Kinetic Models in Stability Studies**

Predicting the shelf life and **stability of the drug product** in stability studies is made easier by figuring out if the degradation follows zero-order or first-order kinetics. These kinetic

models offer a framework for comprehending how environmental elements like temperature and humidity affect the pace of degradation and aid in determining a product's expiration date. The product will lose the same amount of medication over a certain amount of time if degradation proceeds according to zero-order kinetics. The product will gradually lose a fixed percentage of the medication if degradation proceeds according to first-order kinetics.

1.2.2. ICH Guidelines for Stability Testing

Standardised, globally recognised rules for performing stability testing on pharmaceutical products are provided by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Throughout the course of its intended shelf life, a drug product should retain its identity, strength, quality, purity, and efficacy, according to these principles. For drug substances and drug products, stability testing aids in determining the best storage conditions and expiration dates.

- **Purpose and Importance**

Stability testing's main objective is to produce accurate information on how environmental elements like light, humidity, and temperature impact a pharmaceutical product's quality over time. Regulatory submissions, storage recommendations, shelf-life calculations, and guaranteeing the product's safety and efficacy through the end of its intended usage all depend on this information.

ICH Q1A(R2): Stability Testing of New Drug Substances and Products

This guideline, which focusses on novel pharmacological compounds and their formulations, is the cornerstone of ICH stability testing. It lists all of the required stability investigations, including accelerated, intermediate, and long-term studies. The guideline also gives specific details about the length of studies (e.g., 6 months for accelerated, 12 months or more for long-term) and storage conditions (e.g., 25°C ± 2°C/60% RH ± 5% for long-term).

Types of Stability Studies

1. **Long-Term Stability Studies:** Conducted in the conditions that are suggested for storage in order to evaluate the real-time stability and determine the shelf life.

2. **Accelerated Stability Studies:** often out under high temperatures and relative humidity (for example, forty degrees Celsius and seventy-five percent relative humidity) in order to hasten the degradation process and forecast the long-term stability of the material.

3. **Intermediate Studies:** Conducted when a considerable shift is seen under expedited conditions, often at a temperature of 30 degrees Celsius and a relative humidity of 65%.

These different studies provide a comprehensive understanding of the product's stability under various scenarios.

ICH Q1B: Photostability Testing

The evaluation of the effects of light exposure on pharmacological substances and products is the primary emphasis of this guideline. For the purpose of determining the photostability of the product, it is necessary to conduct laboratory tests in both artificial and natural light conditions. Samples are subjected to varying levels of light, and any changes that occur in terms of their physical appearance, potency, or chemical makeup are analysed.

ICH Q1C: Stability Testing for New Dosage Forms

When a new dosage form (such as tablets, injections, or suspensions) is created utilising an already-approved drug ingredient, ICH Q1C covers the stability testing requirements. The guideline, which is customised to the unique features of the new dosage form, usually calls for the same research design as Q1A(R2) and guarantees that the new form maintains quality under designated storage circumstances.

ICH Q1D: Bracketing and Matrixing Designs

Manufacturers can use bracketing and matrixing techniques to reduce the number of stability tests by following this recommendation. Only the extremes—such as the greatest and lowest strengths or package sizes—are examined in bracketing, whereas a portion of all the samples tested at each time point are tested in matrixing. These methods are helpful for effectively handling a large number of comparable samples.

ICH Q1E: Evaluation of Stability Data

To interpret stability data, ICH Q1E offers statistical techniques and criteria for making decisions. It provides guidance on how to assess trends in degradation, calculate shelf life, and

decide if a product stays within specifications over time. To determine expiration dates depending on the rate of degradation, regression analysis is frequently utilised.

ICH Q1F: Stability Data for Climatic Zones III and IV

This recommendation was created to meet the requirements for stability testing of goods sold in hot, muggy nations. The concepts of Q1F are still applied to Zone III (hot/dry) and Zone IV (hot/humid) regions, notwithstanding its formal withdrawal. These nations frequently use 30°C/65% RH or 30°C/75% RH for long-term storage.

The international standard for evaluating a pharmaceutical's shelf life and storage circumstances is the ICH stability testing guidelines. In the end, they safeguard public health by assisting producers in ensuring the long-term safety and effectiveness of their products, facilitating regulatory approval across various locations. Following these recommendations is crucial to preserving quality control and guaranteeing that pharmaceutical items operate consistently from manufacturing to final usage.

1.3 THEORIES OF DISPERSION

Mixtures in which one material (the dispersed phase) is scattered throughout another (the continuous or dispersion medium) are known as dispersion systems. Pharmaceutical formulations such as suspensions, emulsions, aerosols, and colloids depend heavily on these systems. The uniformity of the dispersed particles is crucial for the durability, bioavailability, and therapeutic efficacy of numerous pharmaceutical products. Dispersion theories aid in the creation of stable formulations and the comprehension of particle interactions.

Types of Dispersion Systems

Dispersion systems are classified based on particle size of the dispersed phase:

1. Molecular Dispersions – For example, real solutions, such as glucose in water, are examples of particles that are smaller than one nanometre.

2. Colloidal Dispersions – The size of particles can range from 1 nanometre to 0.5 micrometres, and this includes gels, micelles, and specific protein solutions.

3. Coarse Dispersions – There are particles that are larger than 0.5 μm, such as those found in suspensions and emulsions. These particles are commonly observable through the use of a microscope and are more likely to undergo sedimentation or creaming behaviour.

1. Kinetic Theory (Brownian Motion)

The kinetic theory explains how collisions with dispersion medium molecules cause particles in colloidal dispersions to move randomly and continuously. Brownian motion is the name given to this action . In colloidal dispersions, Brownian motion keeps the particles uniformly distributed and inhibits sedimentation. However, additional stabilising techniques are required in coarse dispersions such as suspensions or emulsions since the particle size is too big for Brownian motion to successfully avoid settling.

2. Electrical Double Layer Theory

This idea is predicated on the observation that, when floating in a liquid, scattered particles frequently have an electrical charge. An electrical double layer is created around a charged particle by drawing a layer of counter-ions from the surrounding medium. The double layer is composed of two parts:

- Stern layer: An inner layer consisting of counter-ions that are firmly bonded.
- Diffuse layer: The outer layer of loosely held ions that extends into the surrounding medium.

The electric potential at the intersection of these two layers is known as the zeta potential, and it is crucial in establishing the system's stability. Strong particle repulsion from a high zeta potential inhibits aggregation. Sedimentation or flocculation may result from the attractive forces taking over if the zeta potential is too low.

3. DLVO Theory (Derjaguin-Landau-Verwey-Overbeek Theory)

DLVO theory is a comprehensive explanation of the stability of colloidal systems, considering two major forces acting between particles:

- Attractive van der Waals forces: These are short-range forces that pull particles together.

- Repulsive electrostatic forces: Originating from the electrical double layer, these forces push particles apart.

This theory states that the equilibrium between these forces determines the net contact between particles. The system stays stable if repulsion takes centre stage. Instability may result from particle aggregation if attraction is strong. The stability of a colloidal dispersion and the likelihood of particle clumping over time are predicted by the DLVO theory.

4. Steric Stabilization Theory

When long-chain polymers or surfactants adsorb onto the surface of dispersed particles, steric stabilisation takes place. These chains form a physical barrier that keeps particles from approaching too closely by extending into the surrounding medium. Osmotic effects and entropy shifts cause the chains to repel one another when two of these coated particles get close to one another. The dispersion is successfully stabilised by this steric barrier. When electrostatic stabilisation is inadequate or the medium contains high ionic strength that could compress the double layer, steric stabilisation is very helpful.

5. Interfacial Film Theory (Specific to Emulsions)

The interfacial film theory applies to emulsions and focuses on the role of emulsifying agents in forming a stable film around the droplets of the dispersed phase. In order to create a protective barrier at the interface, surfactants or polymers lower the interfacial tension between two immiscible liquids (such as water and oil). Droplets are kept from combining or recombining into a single phase by this film. The stability of the emulsion increases with the strength and elasticity of the film. The type and stability of the emulsion are significantly influenced by the emulsifying agent selection.

6. Oriented Wedge Theory

The molecular orientation and shape of the emulsifying agents dictate whether an oil-in-water (O/W) or water-in-oil (W/O) emulsion will form, according to this hypothesis, which also explains emulsion stability. At the oil-water interface, molecules with a hydrophilic head and a lipophilic tail align themselves in a particular way to form a wedge. The emulsion tends to be oil-in-water if the hydrophilic component is predominant. A water-in-oil emulsion is

preferred if the lipophilic component predominates. This orientation establishes the type of emulsion in addition to stabilising the droplets.

Dispersion theories offer a scientific foundation for comprehending and managing the behaviour of scattered systems in drug formulations. Every theory provides important information about stabilising emulsions, suspensions, and colloids, regardless of whether it is based on electrical charge, particle motion, interfacial phenomena, or molecular structure. Formulation scientists can create more stable and effective solutions that guarantee reliable drug distribution and therapeutic impact by putting these theories to use.

1.3.1 Thermodynamic and Kinetic Aspects

In pharmaceutical formulations, dispersion systems like emulsions, suspensions, and colloids are essential. In these systems, one phase—usually a solid, liquid, or gas—is distributed within another immiscible phase. Thermodynamic and kinetic characteristics are two important elements that control the behaviour, stability, and efficiency of these dispersions. These factors affect the system's shelf life, physical stability, and the efficiency of the active pharmaceutical ingredient's (API) delivery. Formulators can produce more stable and potent pharmaceutical medicines by comprehending the kinetic and thermodynamic concepts underlying dispersions.

- **Thermodynamic Aspects of Dispersions**

Aspects of thermodynamics deal with the system's energy condition and propensity to reach a lowest free energy state. Due to the enormous interfacial regions between the continuous phase and the dispersed phase, the majority of pharmaceutical dispersion systems are thermodynamically unstable. As the system tries to lessen interfacial tension and transition back to a more stable, lower-energy state, the increasing surface area raises the free energy. For example, when water and oil are mixed to create an emulsion, the system's free energy is increased due to the broad contact between the water and oil droplets. In order to reduce this energy, the system naturally leans towards phase separation. Long-term thermodynamic instability of the system persists despite surfactants' ability to temporarily stabilise the dispersion and lower interfacial tension.

Certain systems, such as micellar solutions or microemulsions, may be thermodynamically stable because of an innate balance of repulsive and attractive forces and spontaneous production under particular circumstances. However, when it comes to pharmaceutical

dispersions, these systems are the exception rather than the rule.

- **Kinetic Aspects of Dispersions**

A dispersion system's rate of change is the subject of kinetic aspects. For a considerable amount of time, a dispersion may be kinetically stable but thermodynamically unstable. This indicates that even if the system naturally separates, it does so at a slow enough rate to keep the formulation working for the duration of its targeted shelf life.

Particle size, medium viscosity, phase-to-phase density variations, and the presence of stabilising chemicals are some of the variables that affect kinetic stability. For instance, decreasing particle size can counteract sedimentation in suspensions by increasing Brownian motion. In a similar vein, slowing down the flow of dispersed particles by raising the viscosity of the continuous phase might postpone processes like creaming or sedimentation.

By creating a coating over droplets that prevents them from merging, surfactants in emulsions not only reduce interfacial tension, a thermodynamic factor, but also act as a kinetic barrier to coalescence. By doing this, destabilisation processes are slowed down and the emulsion's functioning and appearance are preserved over time.

- **Comparison and Practical Implications**

The implications for formulation design are where thermodynamic and kinetic aspects diverge most. While kinetic factors dictate how long a realistically unstable system may be used, thermodynamic factors determine whether a system can exist stably in theory. Since most formulations must remain stable for a specified shelf life rather than being permanent, kinetic stability is more important in real-world pharmaceutical applications.

To keep goods physically stable, formulators mostly rely on kinetic control techniques. To slow down the processes of degradation and separation, they include the addition of viscosity enhancers, surfactants, polymers, and other excipients. Although the system may eventually malfunction, these precautions guarantee that the product will remain safe, effective, and of high quality for the duration of its intended use.

To sum up, the formulation and stability of pharmaceutical dispersion systems are greatly influenced by thermodynamic and kinetic factors. Kinetic concepts provide useful tools to slow down destabilisation processes and preserve product usability, while thermodynamic

principles emphasise the intrinsic instability of most dispersions due to high interfacial energy. In order to ensure patient safety and therapeutic efficacy, formulations that are both financially feasible and scientifically sound must be developed with a thorough understanding of both factors.

1.4 PHARMACEUTICAL DISPERSIONS

In pharmaceutical sciences, where one phase (the dispersed phase) is distributed within another (the continuous phase), pharmaceutical dispersions are crucial dose forms. These systems are intended to improve pharmaceutical medications' solubility, stability, bioavailability, and effectiveness—especially those that are unstable in solution or poorly soluble in water. Pharmaceutical scientists can create medicines that guarantee consistent drug distribution, simplicity of administration, and improved therapeutic results by dispersing the active pharmaceutical ingredient (API) in an appropriate medium. Dispersions are essential to many contemporary drug delivery systems and are frequently employed in oral, topical, parenteral, and ocular formulations.

Classification of Pharmaceutical Dispersions

Pharmaceutical dispersions can be classified into three broad categories based on particle size:

1. **Molecular Dispersions**: When the particles are smaller than 1 nm, these are genuine solutions. Electrolyte and nonelectrolyte solutions with fully dissolved solute molecules are two examples.
2. **Colloidal Dispersions**: The particle sizes of these range from 1 nm to 1 μm. The scattered particles do not settle out with gravity and are invisible to the unaided eye. Micelles, gels, and microemulsions are a few examples.
3. **Coarse Dispersions**: In these systems, the particle size exceeds 1 μm, and particles are large enough to be seen under a microscope. Examples include suspensions (solid in liquid) and emulsions (liquid in liquid).

Suspensions: Properties and Applications

Suspensions are a type of coarse dispersion in which insoluble solid particles are dispersed in a liquid vehicle, usually water or an aqueous medium. They are commonly used for administering insoluble drugs orally, topically, or via injection. Suspensions offer advantages

such as improved stability over solutions for certain APIs, ease of swallowing for pediatric or geriatric patients, and better taste masking. However, they present challenges including sedimentation of solid particles, caking at the bottom of the container, and non-uniform dosing if not properly shaken before use. Formulating a stable suspension requires the use of suspending agents (e.g., carboxymethyl cellulose), wetting agents (e.g., polysorbates), and flocculating agents to prevent aggregation or caking. Proper control of viscosity, particle size, and zeta potential is crucial for physical stability and effective drug delivery.

Emulsions: Types and Stabilization

Two immiscible liquids, usually water and oil, combine to form emulsions, which are biphasic systems in which one liquid is distributed as tiny droplets inside the other. Emulsions are categorised as either water-in-oil (W/O) or oil-in-water (O/W) based on which phase creates the continuous medium. W/O emulsions are frequently utilised in topical formulations, whilst O/W emulsions are typically utilised for oral and intravenous administration. Emulsifying substances, such as surfactants (such lecithin and polysorbate 80), stabilise emulsions by lowering interfacial tension and preventing droplets from coalescing. Since emulsion systems are susceptible to phase separation, flocculation, creaming, and coalescence over time, physical stability is a major concern. For the development of stable and efficient emulsion-based medicinal products, high-shear homogenisation, the selection of an adequate surfactant blend, and control of droplet size distribution are crucial.

Colloidal Dispersions: Advanced Drug Delivery Systems

A significant class of pharmaceutical dispersions are colloidal dispersions, in which the dispersed particles range in size from one nanometre to one micron. Liposomes, micelles, nanoemulsions, and polymeric nanoparticles are examples of these systems. Improved solubility of hydrophobic medications, targeted distribution to particular tissues or organs, and controlled or prolonged drug release are only a few benefits of colloidal drug delivery systems. Especially when applied topically or parenterally, their tiny particle size promotes improved absorption and biodistribution.

DOI 10.5281/zenodo.15826883. https://doi.org/10.5281/zenodo.15826884



Figure 1.4: Colloidal Dispersions

Steric or electrostatic stabilisation is used to keep colloidal dispersions stable, and factors including particle size distribution, surface charge (zeta potential), and the presence of stabilisers or surfactants affect how they behave. These systems are an essential part of nanomedicine and are being utilised more and more in the treatment of chronic illnesses, cancer treatment, and vaccine delivery.

Therapeutic and Formulation Considerations

Pharmaceutical dispersions offer a great deal of versatility in the design of dosage forms and therapeutic uses. For instance, emulsions can be utilised to increase the bioavailability of lipophilic medications, whereas suspensions can be used to modify drug release rates through the application of polymer coatings or particle size manipulation. Emulsions and colloidal gels can enhance skin penetration and offer moisturising properties in topical applications. Nanoemulsions and liposomal formulations can target certain organs, lower toxicity, and enhance therapeutic results when administered parenterally. The physicochemical characteristics of the medication and the dispersion system, such as solubility, stability, pH, viscosity, and excipient compatibility, must be taken into account by formulation scientists. Drug efficacy and patient safety also depend on proper labelling and packaging, such as "Shake Well Before Use" for suspensions.

To sum up, pharmaceutical dispersions are a flexible and crucial class of drug delivery methods that enable the creation of a variety of active components, particularly those with stability problems or limited water solubility. Pharmaceutical scientists can greatly enhance medication performance, patient compliance, and therapeutic efficacy by carefully choosing the kind of dispersion system and refining the formulation's constituent parts. Colloidal and

DOI 10.5281/zenodo.15826883. https://doi.org/10.5281/zenodo.15826884

nanoscale dispersions continue to transform contemporary pharmacology by providing creative answers to challenging therapeutic problems, thanks to developments in nanotechnology and biopharmaceutical engineering.

1.4.1 Emulsions – Types, Preparation & Stability

An example of a colloidal dispersion system is an emulsion, which is a stable mixture made up of two immiscible liquids, usually water and oil. The food, cosmetics, and pharmaceutical sectors all make extensive use of emulsions to distribute active substances, improve bioavailability, and produce a variety of desired effects.



Figure 1.5: Emulsion

Emulsions can boost the absorption and solubility of hydrophobic (oil-soluble) medications. The creation of dependable and efficient products requires an understanding of emulsion kinds, preparation techniques, and stability factors.

- **Types of Emulsions**

Emulsions are generally classified into two types based on the phase in which the dispersed phase (oil droplets) is dispersed:

1. **Oil-in-Water Emulsions (O/W)**

Oil droplets are distributed throughout a continuous aqueous phase in an oil-in-water (O/W) emulsion. The most often utilised kind of emulsion in cosmetic and medicinal formulations is this one. Oral medication formulations, intravenous emulsions, and creams are a few examples.

Properties:

- Since water is the continuous phase, they are better suited for uses requiring water-based delivery.
- O/W emulsions are perfect for topical applications like lotions and creams since they are usually light and spread easily.
- Compared to water-in-oil emulsions, these emulsions are less greasy, more stable, and offer superior bioavailability for water-soluble medications.

Examples:

- Pharmaceutical liquid emulsions for oral administration (e.g., castor oil emulsion).
- Topical preparations such as moisturizers and sunscreens.

2. Water-in-Oil Emulsions (W/O)

In a water-in-oil (W/O) emulsion, water droplets are dispersed in an oily continuous phase. W/O emulsions are used for more specialized applications, often where the formulation needs to provide a longer-lasting, more occlusive effect.

Properties:

- The continuous phase is oil, making these emulsions more hydrophobic and less likely to evaporate.
- W/O emulsions are typically thicker, greasier, and more occlusive, which helps prevent water loss from the skin. This makes them ideal for products like moisturizers for dry skin or sunscreens.
- These emulsions tend to be more stable in terms of long-term storage as oil acts as a better barrier to oxidation.

Examples:

- Ointments, creams, and some moisturizers.
- Parenteral formulations such as oil-based injectables.

3. Multiple Emulsions (W/O/W or O/W/O)

Complex emulsions known as multiple emulsions are made up of a mix of water and oil phases that can form an O/W/O (oil-in-water-in-oil) or W/O/W (water-in-oil-in-water) structure. These emulsions serve as carriers for active substances and are employed for controlled drug release.

Properties:

- These emulsions are capable of encapsulating hydrophobic drugs in the oil phase and hydrophilic drugs in the aqueous phase.
- Used in controlled-release formulations, they can help modulate the release rate of active ingredients.

Examples:

- Encapsulated drug formulations.
- Biodegradable microcapsules used for controlled release.

Preparation of Emulsions

The process of creating an emulsion is combining two immiscible liquids, usually water and oil, then stabilising them with an emulsifying agent (emulsifiers or surfactants). The following are the essential steps in emulsion preparation:

a) Selection of Ingredients

Making stable emulsions requires selecting the right emulsifying agent, oils, and water phase. In order to stabilise the dispersed phase and avoid phase separation, the emulsifier is essential. Surfactants like cetyl alcohol, stearyl alcohol, lecithin, and polysorbates are examples of common emulsifiers.

b) Methods of Preparation

There are several methods used to prepare emulsions:

- **The Dry Gum Method (Continental Method):** This method involves mixing oil and the emulsifying ingredient (often gum) in a 4:2:1 oil:water:gum ratio. To create a smooth emulsion, this is subsequently triturated in a mortar.
- **The Wet Gum Method:** To create a mucilage, water and the emulsifying agent—typically gum—are combined first, and then oil is progressively added. Emulsions are frequently prepared on a laboratory scale using this technique.
- **The Bottle Method:** This straightforward small-scale preparation method involves mixing the oil, water, and emulsifier in a bottle and giving it a good shake.
- **High-Shear Mixing:** This method breaks down the oil droplets into smaller particles and creates a stable emulsion by using high-speed mechanical mixers or homogenisers. Emulsions and nanoemulsions are frequently produced on a wide scale using this technique.
- **Microfluidization:** In order to create nanoemulsions, a mixture is passed through a microfluidizer at high pressures to decrease the droplet size.

c) Incorporation of Active Ingredients

The active pharmaceutical ingredients (APIs) or excipients can be added to the system after the emulsion is ready. Depending on the characteristics of the API and the desired release profile, this may include straightforward mixing or the application of more complex strategies.

Stability of Emulsions

Because emulsions are susceptible to physical changes such phase separation, creaming, flocculation, coalescence, and cracking, stability is a crucial consideration in their composition. The balance of forces acting on the dispersed droplets, such as the interfacial tension between the phases, droplet size, and the impact of external factors like temperature, pH, and ionic strength, determines the physical stability of emulsions.

Types of Instability

- **Creaming:** When the scattered droplets in the continuous phase rise or fall as a result of density variations, creaming takes place. The water phase increases in W/O emulsions, but the oil phase tends to rise in O/W emulsions. Shaking the emulsion frequently reverses creaming.

- **Flocculation:** Flocculation lowers the emulsion's homogeneity when the scattered droplets group together or form loose clumps.
- **Coalescence:** Phase separation may result from coalescence, which happens when the droplets combine to produce larger droplets. Usually, this cannot be reversed.
- **Cracking (Breaking):** Cracking happens when the emulsion totally separates into its constituent phases, typically as a result of incorrect formulation or emulsifier loss.

Factors Affecting Emulsion Stability

- **Emulsifier Selection:** One of the most crucial elements affecting emulsion stability is the emulsifier selection. To stabilise the oil-water interface, an effective emulsifier needs to be both hydrophilic and lipophilic.
- **Particle Size:** By decreasing the surface area and increasing the effectiveness of emulsifiers, smaller droplet sizes typically result in improved emulsion stability. Compared to traditional emulsions, microemulsions and nanoemulsions are more stable.
- **Viscosity:** By impeding droplet mobility, increasing the viscosity of the continuous phase can lower the rate of creaming.
- **pH and Ionic Strength:** The charge and stability of the emulsifier can be impacted by the emulsion's pH and ionic strength. For instance, the emulsifier may become destabilised at specific pH levels if it loses its charge.
- **Temperature:** While low temperatures can result in solidification or phase separation, high temperatures can raise the system's kinetic energy and encourage coalescence.

Stabilization of Emulsions

To improve the stability of emulsions, various techniques are used:

- **Use of Surfactants:** By reducing the interfacial tension between the water and oil phases, surfactants or emulsifiers promote stability and the creation of smaller droplets. Cetyl alcohol, lecithin, and polysorbates are a few examples.
- **Addition of Thickeners:** The rate of creaming may be slowed by thickeners like carbomers or xanthan gum, which raise the continuous phase's viscosity.
- **Electrostatic Stabilization:** Electrostatic repulsion between the droplets can stop them from aggregating by raising their electrostatic charge.

DOI 10.5281/zenodo.15826883. https://doi.org/10.5281/zenodo.15826884

- **Steric Stabilization:** By physically enclosing droplets and avoiding coalescence, high molecular weight emulsifiers can offer steric stabilisation.

Emulsions are useful and adaptable pharmacological formulations that increase bioavailability, boost patient compliance, and facilitate the delivery of hydrophobic or weakly water-soluble medications. Choosing the appropriate components, procedures, and techniques is essential to the production and stability of emulsions. Although emulsion stability is still a problem, formulators can create stable and efficient products by carefully selecting stabilisers, emulsifiers, and production techniques. Optimising drug delivery systems and attaining the intended therapeutic outcomes require an understanding of emulsion behaviour and applications.

1.4.2 Suspensions – Formulation and Evaluation

A pharmaceutical formulation known as a suspension is one in which solid particles are distributed throughout a liquid media. Because stabilisers or dispersion agents work to keep these solid particles suspended, they are usually insoluble in the liquid phase. Since the formulation enables the active pharmaceutical ingredient (API) to be provided in a liquid state for easier administration, particularly when solid oral dose forms are impractical, suspensions are frequently employed to deliver medications that are poorly soluble in water.



Figure 1.6: Suspensions

Pharmaceutical, cosmetic, and food products all make extensive use of suspensions, which are frequently injected, applied topically, or taken orally. Careful formulation and assessment are required to guarantee appropriate dosage, stability, and bioavailability in order to produce a stable and effective solution.

a. Formulation of Suspensions

A number of essential ingredients must be chosen and combined while creating suspensions in order to guarantee that the medication stays in a consistent, stable, and efficient state. The drug substance (API), a liquid vehicle, stabilisers, and other excipients to maximise the product's performance are usually included in these components.

Active Pharmaceutical Ingredient (API)

A medication that is either insoluble or only weakly soluble in water usually serves as the API in a suspension. Antibiotics, antacids, and steroids are typical examples of APIs used in suspensions. Because smaller particles offer a larger surface area for breakdown and more effective absorption, the API's particle size is crucial.

Vehicle or Dispersion Medium

The liquid portion of the suspension that acts as a medium for the medication particles to stay suspended is called the vehicle. Although water is the most widely utilised vehicle, oils or other aqueous solutions may be employed for specific formulations. To keep the particles from settling too quickly, the vehicle needs to have the right viscosity and rheological characteristics.

Oral suspensions are frequently made in aqueous vehicles, however non-aqueous vehicles can be employed when water-based systems are inappropriate, such as for medications that are poorly soluble in water or to increase the suspension's stability.

Suspending Agents

The purpose of suspending agents, sometimes referred to as thickeners or viscosity enhancers, is to make the vehicle more viscous and aid in maintaining the suspension of the solid particles. These substances keep the particles from settling or aggregating and enhance the suspension's flow characteristics. Typical suspending agents consist of:

- Hydroxypropyl methylcellulose (HPMC)
- Xanthan gum
- Carboxymethyl cellulose (CMC)
- Acacia gum

The ability of a suspending agent to preserve homogeneity and avoid sedimentation over time is typically used to evaluate its efficacy.

Flocculating Agents

Flocculating substances aid in the formation of loose aggregates, or "flocs," of particles that are easier to resuspend and do not settle too quickly. Usually, these substances lower the energy needed to scatter the particles. Common flocculating agents include electrolytes like magnesium sulphate, calcium sulphate, and sodium chloride.

Stabilizers

In order to improve the suspension's stability and avoid problems like aggregation, crystallisation, or phase separation, stabilisers are compounds that are added. They include the following and function by lowering the interfacial tension between the liquid phase and the solid particles:

- Surfactants like polysorbates (e.g., polysorbate 80)
- Polyethylene glycols (PEG)
- Gums and resins like guar gum or acacia

By keeping the particles from clumping together to form bigger aggregates that would jeopardise drug delivery, these stabilisers aid in preserving the suspension's physical integrity.

Preservatives

Preservatives are added to suspensions to prevent microbial contamination during storage and use. Common preservatives include:

- Methylparaben
- Propylparaben
- Benzalkonium chloride

Preservatives must be carefully selected to avoid interactions with the API and other excipients.

Evaluation of Suspensions

In order to make sure the finished product is safe, stable, and useful for usage, the suspension must go through a thorough evaluation process to determine its physical and chemical characteristics. The evaluation procedure takes a number of things into account.

Particle Size and Distribution

The medicine's bioavailability is directly impacted by the size of the dispersed drug particles. Better absorption and dissolution rates result from the increased surface area of smaller particles. To prevent issues like caking, sedimentation, or poor dissolving, the particle size should be regulated. The following methods are employed to assess particle size:

- Microscopy (light microscopy or electron microscopy)
- Laser diffraction
- Dynamic light scattering

The particle size distribution should be narrow, ensuring uniformity in drug release and dosing.

Sedimentation Rate

Particles in suspensions often settle over time as a result of gravity, creating a sediment at the bottom. Because it dictates how frequently the solution needs to be shaken or stirred before administration, the pace at which this sedimentation takes place is significant.

The quantity of settled particles in a specific amount of time is measured by sedimentation volume. The following formula can be used to determine the sedimentation rate:

$$R = \frac{h_0 - h_t}{h_0} \times 100$$

Where:

- R is the sedimentation rate
- h0 is the initial height of the suspension

- ht is the height of the suspension at time t

A lower sedimentation rate indicates better stability.

Viscosity

One important factor that influences the suspension's stability and ease of administration is viscosity. It is necessary to make sure the suspension moves freely without allowing the particles to settle too quickly. A rotating viscometer or a Brookfield viscometer can be used to test viscosity. In order to minimise sedimentation and facilitate pouring without making the formulation overly thick, the viscosity should be adjusted.

Redispersibility

The ability of a suspension to revert to its initial homogeneous state following agitation or shaking is known as redispersibility. The dispersed particles should not form big aggregates that are hard to redistribute, and suspensions should be easy to shake. This is essential to guarantee that the active component is delivered in a constant quantity with each dose.

pH

Both the formulation's stability and the drug's solubility depend on the suspension's pH. To avoid instability or degradation, the pH should be in line with the active ingredient. For instance, at very high pH levels, some medications may hydrolyse.

Microbial Testing

To be safe for usage, suspensions need to be free of microbiological contamination. To verify that the preservatives in the suspension are successful in avoiding contamination, microbial testing is usually carried out.

Stability Testing

To assess the suspension's long-term performance under varied storage circumstances, such as temperature, humidity, and light exposure, stability tests are carried out. In order to speed up possible degradation, formulations are exposed to higher-than-normal storage temperatures during stability testing, which usually complies with ICH recommendations for drug stability.

For the administration of insoluble or poorly soluble medications, suspensions are a crucial pharmaceutical dosage form because they offer a liquid medium that is simpler to apply topically or swallow. In order to guarantee stability, homogeneity, and efficient drug administration, proper suspension formulation necessitates careful selection of excipients, including the vehicle, suspending agents, flocculating agents, and preservatives. Suspensions must be thoroughly evaluated to guarantee their long-term stability, efficacy, and safety. To produce dependable, high-quality suspension formulations, factors such as particle size, viscosity, sedimentation, and redispersibility must be well monitored.

1.4.3 SMEDDS – Concept and Development

Pharmaceutical formulations known as Self-Emulsifying Drug Delivery Systems (SMEDDS) are intended to increase the solubility and bioavailability of medications that are not particularly soluble in water. SMEDDS, a subclass of emulsions, are made up of a blend of oils, co-surfactants, and surfactants that naturally create fine emulsions when added to an aqueous medium (like gastrointestinal fluids). These emulsions are quite helpful for medications that are not very soluble in water since they can increase the drug's solubility and absorption. SMEDDS is a cutting-edge drug delivery technology that can solve the problems brought on by many medications' poor solubility in the digestive system.

- **Concept of SMEDDS**

Based on the kind of emulsions they produce when combined with an aqueous phase, SMEDDS—isotropic mixes of oils, surfactants, and co-surfactants—can be divided into several groups. Usually, they include:

- **Oils or Lipids** – These are the formulation's lipid constituents. Medium-chain triglycerides (MCT), long-chain triglycerides (LCT), and other oils are examples of lipids that aid in drug dissolution in formulations and are essential for solubilising medications that are not very water soluble.
- **Surfactants** – Emulsifiers, also known as surfactants, aid in reducing the surface tension between the water and oil phases. Because of their great stability, minimal toxicity, and high efficiency, non-ionic surfactants are frequently utilised. Solutol HS15, polysorbates, and polyethoxylated castor oil (Cremophor EL) are a few examples.

- **Co-surfactants** – Co-surfactants are usually utilised to improve the system's emulsification qualities and further lower the interfacial tension. They are frequently alcohols, such as polyethylene glycol (PEG), propylene glycol, or ethanol.

The idea behind SMEDDS is that the system naturally creates a fine emulsion, frequently in the form of micro or nano-sized droplets, when it is put into an aqueous environment, like the gastrointestinal (GI) tract. The solubility and bioavailability of weakly water-soluble medications are improved by this emulsion, which significantly expands the surface area available for drug absorption.

➢ **Development of SMEDDS**

From formulation to testing and optimisation, the creation of SMEDDS entails a number of crucial factors and processes. The objective is to design a system that optimises drug solubilisation while preserving stability, administering the medication with ease, and delivering reliable results. The steps used in the creation of SMEDDS are listed below:

a. Selection of Components

Choosing the appropriate components is the first and most important stage in creating a SMEDDS formulation. This entails selecting the proper co-surfactant, surfactant, and oil phase. The selection of these elements is contingent upon:

- **Solubility of the Drug** – Particularly for medications that are weakly soluble, the oil phase needs to have a high ability to solvate or dissolve the drug. Additionally, the medicine must be soluble in the surfactants in order for them to create stable emulsions.
- **Toxicity and Biocompatibility** – Every element of the SMEDDS needs to be biocompatible and non-toxic, especially when taken orally. The gastrointestinal mucosa shouldn't become irritated or poisoned by the surfactants and co-surfactants.
- **Ease of Manufacturing** – In large-scale manufacturing, the chosen oils, surfactants, and co-surfactants must be simple to handle and process without resulting in instability or exorbitant expenses.

b. Preparation of SMEDDS

Once the components are selected, SMEDDS are usually prepared by the following methods:

- **Melting Method** – Using this procedure, the oil and surfactant are melted together at a temperature higher than the solid components' melting points. The co-surfactant is then added to finish the system after the medicine has been dissolved in this mixture. The system is allowed to cool when it has reached homogeneity.
- **Solvent Evaporation Method** – This procedure involves dissolving the medication, oil, co-surfactant, and surfactant in a solvent. The self-emulsifying combination is then left behind once the solvent has evaporated.
- **High Shear Mixing** – By dispersing the ingredients under high shear forces, high shear mixing can occasionally be utilised to create SMEDDS and promote the development of fine emulsions.

c. Characterization and Optimization

To make sure the final product satisfies the necessary requirements, the SMEDDS formulations must be characterised and optimised after preparation. Among the several characterisation methods are:

- **Emulsification Efficiency** – When exposed to an aqueous phase (such as water or gastrointestinal fluids), the SMEDDS formulation's capacity to emulsify spontaneously is assessed. This is accomplished by the measurement of the emulsion's stability and particle size.
- **Particle Size and Distribution** – For the best drug absorption, the droplets that form in the aqueous medium should have particle sizes that fall within the specified range. Dynamic light scattering (DLS) and laser diffraction are two methods that can be used to measure this.
- **Stability Testing** –The SMEDDS formulation's chemical and physical stability is evaluated across a range of storage circumstances, including temperature and humidity. Over time, stability guarantees that the formulation will continue to be uniform and efficient.
- **In Vitro Drug Release Studies** – The purpose of these investigations is to assess the drug's release efficiency from the SMEDDS formulation in a gastrointestinal simulation. To guarantee that the formulation releases the drug in a way that is suitable for absorption, the release rate should be comparable to the drug's rate of dissolution in vivo.

d. In Vivo Evaluation

In vivo testing is required to verify the effectiveness of the SMEDDS formulation, even though in vitro studies are crucial for preliminary screening. This comprises:

- **Bioavailability Studies** – Usually, the purpose of SMEDDS formulations is to improve the bioavailability of medications that are not very soluble in water. Evaluation of the increase in bioavailability over traditional formulations is aided by in vivo research employing human volunteers or animal models.
- **Pharmacokinetic Studies** – Following the injection of the SMEDDS formulation, these experiments aid in assessing the drug's absorption, distribution, metabolism, and excretion from the body. Improved pharmacokinetic profiles and increased medication absorption are signs that the formulation is working.

e. Scale-Up and Manufacturing

The next stage is scaling up for large-scale manufacturing when the formulation has been refined and proven to be successful. This procedure entails bringing the formulation from a pilot or laboratory size to a commercial production scale while preserving the product's stability and quality. Maintaining consistency, making the most of manufacturing machinery, and guaranteeing product stability over time can all be obstacles to scaling up.

Advantages of SMEDDS

- **Enhanced Bioavailability** – SMEDDS' main benefit is their capacity to improve the solubility and bioavailability of medications that aren't very water soluble, which may result in better therapeutic results.
- **Improved Drug Stability** – SMEDDS can increase a drug's stability by preventing it from breaking down in the gastrointestinal system by solubilising it in a lipid matrix.
- **Ease of Administration** – SMEDDS are easier to administer, particularly for patients who have trouble swallowing solid pills or capsules, because they may be made into liquid dose forms.
- **Reduced Variability in Drug Absorption** – SMEDDS might lessen variation in drug absorption among individuals or under various physiological situations because they increase the solubility and consistency of drug administration.

Limitations of SMEDDS

- **Formulation Complexity** – The formulation procedure for SMEDDS formulations can be complicated and time-consuming due to the need for meticulous optimisation of several components.
- **Manufacturing Challenges** – It might be difficult to maintain consistency and quality over large batches when scaling up SMEDDS formulations for commercial manufacturing.
- **Cost** – SMEDDS formulations may be more costly than conventional drug formulations due to the inclusion of premium excipients, particularly surfactants and co-surfactants.

SMEDDS are a novel way to increase the bioavailability and solubility of medications that aren't very soluble in water. SMEDDS can improve the absorption of medications with low bioavailability by causing spontaneous emulsions to form in the gastrointestinal tract. To guarantee that the finished product is stable, efficient, and safe for use, SMEDDS formulations must be developed and optimised through a rigorous evaluation process, meticulous excipient selection, and manufacturing methods. SMEDDS have a lot of promise for drug administration despite their complexity, particularly for substances that are difficult to administer in conventional dose forms.

1.5 PARENTERAL PREPARATIONS

Pharmaceutical formulations known as parenteral preparations are designed to be administered via injection, infusion, or implantation without going through the digestive system. These formulations are frequently employed to deliver medications precisely and under control, particularly when oral administration is impractical because of issues including poor bioavailability, fast metabolism, or the requirement for a quick onset of action. Many therapeutic fields, such as emergency medicine, anaesthesia, chemotherapy, and biologic treatments, depend on parenteral drug administration. Parenteral preparations must be safe, sterile, and stable because they are directly injected into the circulation or tissues, making them extremely vulnerable to impurities or formulation mistakes.

DOI 10.5281/zenodo.15826883. https://doi.org/10.5281/zenodo.15826884

Types of Parenteral Preparations

Based on how they are supposed to be administered, parenteral preparations can be roughly divided into several types. Among the primary kinds are:

1. Intravenous (IV) Preparations – These are made to be injected directly into the veins, which enables the medication to enter the bloodstream quickly. For medications that need to start working right away or that are not well absorbed when taken orally, IV formulations are utilised.
2. Intramuscular (IM) Preparations – Compared to IV preparations, they are injected into muscle tissues, where they are absorbed into the bloodstream over an extended period of time. When a medicine cannot be administered intravenously or needs to be released gradually, intramuscular injections (IM) are utilised.
3. Subcutaneous (SC) Preparations – They provide longer-lasting medication release but slower absorption than intramuscular injections because they are administered into the tissue beneath the skin. Insulin and certain biologics are frequently prepared subcutaneously.
4. Intradermal Preparations – Usually used for vaccinations or diagnostics, these are injected into the skin.
5. Intra-arterial Preparations – These are injected straight into an artery, typically for targeted local treatments like chemotherapy for a tumour.
6. Implantable Preparations – These preparations are applied to a particular tissue or beneath the skin, where they release medications gradually. This method is often used for hormone replacement therapy or cancer treatment.

Key Characteristics of Parenteral Preparations

Parenteral preparations are distinct from oral and other medicinal dose forms due to certain features. These qualities guarantee the secure and efficient administration of medications:

1. Sterility – Parenteral preparations need to be free of microbial contamination because they are given straight into the body. This is essential for shielding patients from infections and other problems. Strict manufacturing guidelines, filtration, and sterilisation procedures like autoclaving or gamma radiation are used to establish sterility.

2. Pyrogen-Free – Pyrogens, or chemicals that generate fever when injected into the body, must not be present in parenteral formulations. Procedures such as depyrogenation, which involves heat treatment, or filtration with specialised filters can be used to get rid of pyrogens.
3. Aseptic Technique – Aseptic techniques are necessary for the creation of parenteral preparations in order to prevent contamination of the medicine during the preparation and packing process. This calls for the use of sterile tools, regulated spaces, and appropriate handling techniques.
4. Particle-Free – Particulate particles must be avoided in parenteral formulations since it may result in embolism or other issues. During manufacture, strict filtration methods are employed to guarantee that the final product is free of particles.
5. Stability – Parenteral formulations need to be stable both physically and chemically while being stored. The effectiveness of a medicine may be impacted by instability if it causes precipitation or drug breakdown. Temperature, pH, and the presence of preservatives are some of the variables that affect stability.
6. pH and Osmolarity – Parenteral formulations must be chemically and physically stable during storage. If instability results in precipitation or chemical breakdown, it may affect a medication's efficacy. Among the factors influencing stability include temperature, pH, and the presence of preservatives.

Formulation Components of Parenteral Preparations

Parenteral formulations are composed of several components that work together to ensure the effective delivery of the drug:

1. Active Pharmaceutical Ingredient (API) – The medication or biologic responsible for the therapeutic effect is this one. It must be in a form that is compatible with parenteral administration and stable during storage.
2. Excipients – These non-active components support the parenteral preparation's stability and formulation. Typical excipients consist of:
    - Solvents (e.g., water for injection, saline solution, oils)
    - Preservatives (e.g., benzyl alcohol, methylparaben, and propylparaben)
    - Stabilizers (e.g., citric acid, sodium chloride)

- Buffers (e.g., sodium acetate or phosphate buffers) to maintain the pH of the formulation
- Antioxidants (e.g., sodium bisulfite) to prevent oxidative degradation of sensitive drugs

3. Vehicle – The liquid foundation that transports the excipients and active substance is known as the vehicle. Depending on the necessary formulation, common vehicles are oil, saline, or water.
4. Surfactants – When a medicine is poorly soluble in water, surfactants are employed to increase the drug's solubility and the stability of the parenteral solution.

Manufacturing of Parenteral Preparations

Parenteral preparations are made using a complicated process that must be followed precisely to guarantee both quality and safety. The following are the main processes in the production of parenteral preparations:

1. Preparation of Solution or Suspension – A appropriate solvent or vehicle is used to dissolve or suspend the active medication. Surfactants and co-solvents may be employed to help solubilise a medication that is poorly soluble.
2. Filtration and Sterilization – After removing any remaining particles, the solution or suspension is sterilised, usually by autoclaving or passing it through a sterile filter. For heat-sensitive drugs, sterile filtration is preferred to maintain the integrity of the active ingredient.
3. Filling and Packaging – To avoid contamination, the sterile formulation is aseptically loaded into vials, ampoules, or pre-filled syringes. The containers are sealed to preserve sterility until use, and packaging is completed in a sterile setting.
4. Quality Control Testing – Every batch of parenteral preparations is put through a thorough quality control testing process that includes evaluations for drug content, pH, osmolality, particle content, pyrogenicity, and sterility. To make sure the product maintains its efficacy over the course of its shelf life, stability testing is also carried out.

DOI 10.5281/zenodo.15826883. https://doi.org/10.5281/zenodo.15826884

Advantages of Parenteral Preparations

1. Rapid Onset of Action – Parenteral medications are perfect for emergencies or problems that need immediate attention since they are rapidly absorbed into the bloodstream and produce speedier therapeutic effects.
2. Bypassing the GI Tract – Parenteral formulations circumvent gastrointestinal (GI) tract problems such inadequate medication absorption, hepatic first-pass metabolism, and destruction by stomach acid or enzymes.
3. Precise Dosage Control – The unpredictability involved in oral drug delivery is reduced when pharmaceuticals are administered via injection or infusion, which provides for exact control over the dosage.
4. Ideal for Drugs with Poor Oral Bioavailability – Parenteral delivery is an efficient way to ensure that drugs that are poorly absorbed or unstable in the GI system reach their intended target areas.

Challenges in Parenteral Formulations

1. Patient Discomfort – Compared to oral medications, parenteral administrations—particularly injections—can be painful and may result in tissue damage, discomfort, or irritation.
2. Cost of Production – Parenteral medication manufacturing is a complicated procedure that raises production costs because it calls for specialised equipment, aseptic conditions, and strict quality control.
3. Storage and Stability – Parenteral formulations may need special storage conditions (e.g., cold chain logistics) and have limited shelf life, especially if they are biologics or need to be refrigerated.
4. Risk of Infection – The medicine may get contaminated and cause illness if aseptic procedures are not followed during manufacturing, handling, or administration.

In modern medicine, parenteral preparations are essential for administering medications that need to bypass the gastrointestinal tract, act quickly, or have exact dosage. To guarantee their efficacy and reduce hazards, these preparations must adhere to strict sterility, stability, and safety criteria. Although they have several benefits over oral drug delivery, including quick beginning of action and accurate dosage control, they also have drawbacks, including discomfort for patients, expensive production, and the requirement for certain storage

conditions. For parenteral medications to be successful in therapeutic applications, proper development, testing, and manufacturing are necessary.

1.5.1 Large and Small Volume Parenterals

Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs) are the two types of parenteral preparations that are categorised according to the volume of the drug formulation. These groups are differentiated by their dosage, intended use, and mode of administration. The volume is the main distinction between the two; SVPs normally contain 100 millilitres or less of the substance, whereas LVPs contain more than 100 millilitres. While SVPs are intended to provide concentrated medications for therapeutic purposes such hormone therapy, vaccinations, and pain management, LVPs are utilised for intravenous nourishment, fluid replenishment, or gradual drug infusion.

- **Large Volume Parenterals (LVPs)**

Sterile preparations known as large volume parenteral (LVPs) usually include more than 100 millilitres of solution. These solutions are frequently used for intravenous nourishment, fluid and electrolyte replacement, and the gradual administration of drugs over long periods of time. A common method of administering LVPs is infusion, which entails gradually introducing the solution into the bloodstream. Controlled solution distribution and absorption are made possible by this gradual dosing. For patients who are dehydrated, electrolyte imbalanced, or unable to take nutrition orally, LVPs such as hydration solutions, intravenous nutrition, and electrolytes are essential.

- **Uses of Large Volume Parenterals (LVPs)**

The main purpose of LVPs is to restore fluids to patients who have been dehydrated as a result of vomiting, diarrhoea, or excessive perspiration. Additionally, they are used to address electrolyte imbalances that may arise from kidney disease or other illnesses. Furthermore, LVPs play a crucial role in parenteral nutrition (PN), which involves giving vital nutrients intravenously to individuals who are unable to absorb them through their digestive tract. LVPs can also be used for drug infusion, which is a process where some drugs, including antibiotics or chemotherapeutic treatments, must be given gradually over time to guarantee adequate

absorption. Since blood and blood products are usually given in large quantities to patients who have experienced severe blood loss, they are also regarded as LVPs.

- **Characteristics of Large Volume Parenterals (LVPs)**

LVPs' primary characteristic is their high volume, which usually surpasses 100 millilitres. Because they are injected straight into the bloodstream, they need to be sterile, pyrogen-free, and particle-free. Typically, flexible plastic bags or glass containers with infusion ports for simple intravenous line attachment are used to package LVPs. Depending on the patient's requirements, the administration time for LVPs might vary from one hour to several hours because they are frequently used for slow infusion. Furthermore, because LVPs are sensitive to pH, light, and temperature, it is necessary to closely monitor and manage their stability in order to preserve effectiveness over time.

- **Small Volume Parenterals (SVPs)**

Sterile injectable formulations of 100 millilitres or less of the medication solution are known as small volume parenterals, or SVPs. These preparations are intended for accurate, regulated injections and are commonly used for the administration of concentrated medications. SVPs are used for a variety of therapeutic applications, such as emergency drug administration, pain treatment, and vaccinations. They are typically designed for single doses. Because SVP formulations are more concentrated than LVP formulations, a lower, more targeted dosage of medication can be administered.

- **Uses of Small Volume Parenterals (SVPs)**

Depending on the medication and the recommended dosage, SVPs are used to administer concentrated medications, which frequently need to be diluted first. Vaccines, which are usually administered intramuscularly, subcutaneously, or intradermally and frequently come in tiny amounts of 1 to 5 millilitres, are among the common uses for SVPs. SVPs are also employed in emergency scenarios where quick intravenous administration of vital pharmaceuticals, such as atropine or adrenaline, is required. SVPs are frequently used to deliver hormonal medicines, such as insulin or human growth hormone, because of their low dosage requirements and requirement for precise, controlled administration. Additionally, SVPs are

commonly used to provide local anaesthetics and narcotic painkillers for controlled and efficient relief.

- **Characteristics of Small Volume Parenterals (SVPs)**

SVPs are usually designed for single-dose administration and are prepared in lower amounts, usually between 1 and 100 millilitres. Since these formulations are frequently concentrated, they might need to be diluted before being administered. To guarantee patient safety, SVPs, like LVPs, need to be sterile, pyrogen-free, and particle-matter-free. Typically, they come in pre-filled syringes, ampoules, or vials for convenient and regulated administration. The properties of the medicine have a significant impact on the stability of SVPs, and these products need to be handled and maintained carefully to prevent degradation. SVPs are frequently injected or infused quickly over a brief period of time, enabling prompt therapeutic effects, especially in emergency situations.

- **Differences Between Large and Small Volume Parenterals**

The volume is the primary distinction between LVPs and SVPs. SVPs have 100 millilitres or less, but LVPs usually have more than 100 millilitres. While SVPs are concentrated preparations meant for quick injection or infusion, LVPs are typically used for the gradual infusion of fluids, electrolytes, or nutrients over a longer period of time. SVPs are more frequently used for concentrated medications, vaccinations, and emergency drug administration, while LVPs are frequently used for long-term drug infusion, fluid and electrolyte replacement, and more. SVPs are packaged in vials, ampoules, or pre-filled syringes, whereas LVPs are typically packaged in flexible plastic bags or sizable glass containers. Additionally, because of their huge volume and extended administration duration, LVPs need close stability monitoring, whereas SVPs are usually designed for quicker therapeutic results.

- **Manufacturing and Quality Control**

To guarantee the end product's safety, effectiveness, and quality, strict rules must be followed during the manufacturing of both LVPs and SVPs. Both kinds of parenterals are made aseptically, and quality control is essential to guaranteeing that the final goods fulfil the necessary requirements for sterility, pyrogen-free, and particulate-free products. Sterility

testing, pyrogen testing, particle matter testing, pH and osmolarity testing, and stability testing are all examples of quality control tests for LVPs and SVPs. Over the course of their shelf life, these tests guarantee that the parenterals will continue to be safe and effective for patient usage. Maintaining appropriate handling and storage conditions is also necessary to stop product contamination or deterioration.

Both small volume parenterals (SVPs) and large volume parenterals (LVPs) are essential for medical procedures requiring precise and regulated medication delivery. SVPs are made for highly concentrated, single-dose treatments like vaccines and emergency drugs, whereas LVPs are used for fluid replenishment, electrolyte balance, and gradual drug infusion. Both categories must be produced in accordance with stringent quality control criteria to guarantee sterility, safety, and efficacy, despite differences in amount, use, and administration. Healthcare professionals can choose the best medication delivery system for a patient based on their needs and the treatment requirements by being aware of the distinctions between LVPs and SVPs.

1.5.2 Physiological/Formulation Considerations

It is crucial to take into account both the unique formulation properties and the physiological features of the human body when creating parenteral medication formulations. These factors reduce the possibility of negative effects while ensuring that the medication is administered correctly, safely, and in the appropriate dosage. While formulation considerations centre on the medication's chemical composition, stability, and delivery mechanism, physiological factors pertain to the body's interactions with the drug, including absorption, distribution, metabolism, and excretion. A thorough discussion of these factors may be found below:

Physiological Considerations

1. **Absorption and Bioavailability**

Because parenteral drug delivery avoids the gastrointestinal tract and introduces the medicine directly into the circulation, absorption issues are comparatively low. However, elements including blood flow, the injection site, and the drug's composition can still affect the rate of absorption. Because muscle tissue has a smaller blood supply than other tissues, intramuscular (IM) injections may be absorbed more slowly than intravenous (IV) injections. When designing

medications for intramuscular (IM) and intravenous (IV) modes of administration, it is important to consider the slower absorption rates of SC injections.

2. Blood Flow and Tissue Distribution

The blood flow to the tissues and organs plays a major role in how a medicine is distributed throughout the body. A larger percentage of the medicine will be injected into highly perfused organs, such as the liver, kidneys, and heart. Distribution is also influenced by the drug's solubility in blood and tissue fluids as well as its capacity to pass across cell membranes. For instance, hydrophilic medications stay in the bloodstream or extracellular fluids, but lipophilic drugs tend to collect in fatty tissues.

3. Metabolism and Excretion

Effective and efficient medication metabolism must be guaranteed by the design of parenteral formulations. Many medications are metabolised by the liver, which turns them into metabolites or inactive forms that the kidneys can easily eliminate. Parenterally given medications must be designed to provide the intended therapeutic impact prior to metabolism and excretion. The frequency of dosage and the possibility of buildup in the body are significantly influenced by the half-life, or rate of elimination. For example, medications with long half-lives might need to be taken less frequently, whereas medications with short half-lives might need to be taken more regularly.

Formulation Considerations

1. Sterility and Aseptic Technique

Maintaining sterility is one of the most important factors in parenteral formulations. Any microbial contamination can result in severe infections or unpleasant responses since parenteral medications are injected directly into the circulation or tissues. The medicine and its container (such as vials or syringes) must be free of impurities, and the formulation must be made under stringent aseptic conditions. Throughout the manufacturing, packaging, storage, and transportation processes, sterility is preserved. Furthermore, the drug's sensitivity to heat and other sterilising procedures must be taken into consideration when selecting sterilisation techniques like heat or filtration.

2. pH and Osmolarity

Parenteral formulations' pH and osmolarity need to be precisely adjusted to the body's normal levels. The pH of human blood ranges from 7.35 to 7.45, and medications that are noticeably more basic or acidic can irritate tissues or blood vessels. For example, formulas that are basic or acidic may irritate or injure nearby tissue. To make sure the drug solution is isotonic with blood plasma, osmolarity—the concentration of solute particles in a solution—must be changed [48]. While a hypotonic solution (one with a lower solute concentration) can lyse red blood cells, a hypertonic solution (one with a higher solute concentration) can irritate and harm tissue. Formulations are frequently modified to make sure the solution is isotonic or properly buffered in order to prevent these issues.

- **Stability and Shelf Life**

Another crucial formulation factor is drug stability. Throughout its shelf life, a stable medicine keeps its potency, purity, and general efficacy. Temperature, light, humidity, and the chemical makeup of the medicine itself are some of the variables that affect stability. To guarantee that the medication stays effective until its expiration date, the formulation must be made to withstand deterioration during storage. For example, some medications may break down when exposed to air or light, necessitating the use of antioxidants or packing in opaque containers. To estimate the drug's shelf life and identify the best storage settings, stability studies—including accelerated stability testing—are carried out.

3. Viscosity and Injection Site Tolerability

Another important factor to take into account is the viscosity of parenteral formulations. Injecting highly viscous formulations might be challenging, which could cause discomfort for the patient or make it harder to provide the medication. High-viscosity formulations can occasionally be challenging to absorb as well, especially when administered intramuscularly or subcutaneously. In order to facilitate injection and guarantee appropriate absorption, the formulation's viscosity must be decreased. Viscosity can be changed with additives like solvents or surfactants without affecting the stability or efficacy of the medication. Formulations must also be made with non-irritating excipients and cautious pH and osmolarity changes to reduce pain or irritation at the injection site.

4. Compatibility and Excipients

Excipients are inert components that are added to parenteral formulations to help with the administration, stability, or absorption of the medicine. These excipients may consist of surfactants, stabilisers, buffers, and preservatives. Excipients must be chosen carefully so as not to interfere with the active pharmaceutical ingredient (API) in a way that could compromise safety or efficacy. To guarantee that the medicine and excipients stay stable and effective for the duration of the formulation's shelf life, compatibility studies must be carried out. The effectiveness or safety profile of some medications, for instance, may be changed by reactions with preservatives that result in precipitation or changes in the drug's solubility. The effective creation of parenteral medications depends heavily on both formulation and physiological factors. Comprehending physiological aspects including absorption, distribution, metabolism, and excretion guarantees that the medication can be efficiently administered to the intended location within the body. Sterile, pH, osmolarity, stability, viscosity, and excipient compatibility are among the formulation factors that guarantee the drug's safety, effectiveness, and patient tolerance throughout time. Together, these factors inform the development of parenteral formulations that minimise hazards and adverse patient reactions while simultaneously meeting regulatory requirements and delivering the intended therapeutic effects.

1.5.3 Manufacturing and Evaluation

A number of complex procedures are involved in the production and assessment of parenteral formulations to guarantee the greatest calibre, safety, and efficacy of the finished product. Drug formulation is the first step in the manufacturing process, during which the physicochemical characteristics of the active pharmaceutical ingredient (API) are taken into account to create a suitable dosage form (such as a solution, suspension, or emulsion) and select the best administration method (such as intravenous or subcutaneous). To guarantee the stability and solubility of the medicine, excipients such as stabilisers, buffers, preservatives, and solubilizers are added at this stage. The medicine undergoes sterilisation after formulation development; depending on the drug's stability, this may involve heat sterilisation or filtration. medications that are stable at high temperatures are sterilised by heat, whereas medications that are sensitive to heat are sterilised by filtration, in which sterile filters eliminate germs without changing the drug's characteristics. Strict hygiene guidelines are adhered to during the preparation, filling,

and packaging phases, and the aseptic technique is essential throughout this process to prevent contamination. Following preparation and sterilisation, the formulation is put into sterile vials, ampoules, or pre-filled syringes. To prevent contamination, this procedure needs to be carried out in a sterile setting. In order to shield the medication from environmental elements like light, air, and moisture that could jeopardise its stability, packaging is also essential. Parenteral medications are therefore frequently packed in amber glass containers with tamper-evident seals for extra security. Parenteral medicine labels are essential since they include vital information such as the drug's name, concentration, dosage, storage directions, batch number, and expiration date. Proper patient use is ensured and parenteral risks are reduced with clear and precise labelling. A number of testing techniques are used in the evaluation of parenteral formulations to make sure the final product satisfies quality standards. Both quality assurance (QA) and quality control (QC) are essential components of this procedure. In quality control (QC), batches are tested to make sure the drug satisfies requirements such as pH, particulate matter, endotoxin levels, and sterility—all of which are critical for patient safety. Endotoxin testing confirms that the medication is devoid of endotoxins that could result in serious side effects, while sterility testing guarantees that no germs are present. To prevent irritation, the formulation's pH must be within a reasonable range, and particulate matter testing makes sure there are no visible particles that could cause embolism or other issues. The product's shelf life is determined by stability testing, which is carried out under a variety of temperature, humidity, and light settings. Accelerated and real-time stability studies offer important information about the drug's long-term stability.

To make sure the medication is administered at the right concentration and for the right amount of time, release testing assesses how quickly the drug is released from the dosage form. For formulations intended for controlled or gradual release, this is particularly crucial. Because it gives details on how the drug is absorbed, transported, metabolised, and eliminated by the body, pharmacokinetic evaluation is also crucial. This aids in determining the best formulation and guiding dosage schedules. To ensure that there are no negative responses that could impair the medicine's effectiveness, compatibility testing is required to assess how the drug interacts with its delivery method, such as the syringe or IV catheter. Compatibility testing, both in vivo and in vitro, evaluates how the medication behaves in the body and interacts with the delivery method to make sure it works as intended. Parenteral formulations can be created using these rigorous production and assessment procedures to guarantee their excellent quality, safety, and efficacy for patient usage.

REFERENCES

1. *Gopinath, R., & Naidu, R. A. S. (2011). Pharmaceutical preformulation studies–current review. International Journal of Pharmaceutical & Biological Archives, 2(5), 1391-1400.*
2. *Chaurasia, G. (2016). A review on pharmaceutical preformulation studies in formulation and development of new drug molecules. Int J Pharm Sci Res, 7(6), 2313-2320.*
3. *Verma, G., & Mishra, M. K. (2016). Pharmaceutical preformulation studies in formulation and development of new dosage form: A review. Int. J. Pharma Res. Rev, 5(10).*
4. *Bharate, S. S., & Vishwakarma, R. A. (2013). Impact of preformulation on drug development. Expert opinion on drug delivery, 10(9), 1239-1257.*
5. *Ku, M. S. (2010). Preformulation consideration for drugs in oral CR formulation. Oral controlled release formulation design and drug delivery: Theory to practice, 47-69.*
6. *Lieberman, H., Rieger, M., & Banker, G. S. (Eds.). (2020). Pharmaceutical dosage forms: Disperse systems. CRC Press.*
7. *Piao, H., Yang, L., Piao, H., Wang, P., Shi, H., Fang, L., & Cui, F. (2016). A pre-formulation study of a polymeric solid dispersion of paclitaxel prepared using a quasi-emulsion solvent diffusion method to improve the oral bioavailability in rats. Drug development and industrial pharmacy, 42(3), 353-363.*
8. *Ahirwar, K., & Shukla, R. (2023). Preformulation studies: a versatile tool in formulation design. In Drug Formulation Design. IntechOpen.*
9. *Zhang, X., Xing, H., Zhao, Y., & Ma, Z. (2018). Pharmaceutical dispersion techniques for dissolution and bioavailability enhancement of poorly water-soluble drugs. Pharmaceutics, 10(3), 74.*
10. *Tambe, S., Jain, D., Meruva, S. K., Rongala, G., Juluri, A., Nihalani, G., ... & Bolla, P. K. (2022). Recent advances in amorphous solid dispersions: preformulation, formulation strategies, technological advancements and characterization. Pharmaceutics, 14(10), 2203.*
11. *Honmane, S. M. (2017). General considerations of design and development of dosage forms: pre-formulation review. Asian Journal of Pharmaceutics (AJP), 11(03).*

12. *Dios, P., Nagy, S., Pál, S., Pernecker, T., Kocsis, B., Budán, F., ... & Dévay, A. (2015). Preformulation studies and optimization of sodium alginate based floating drug delivery system for eradication of Helicobacter pylori. European Journal of Pharmaceutics and Biopharmaceutics, 96, 196-206.*
13. *Dandage, M. C., Arjun, Y. N., & Bais, S. K. A Review on Preformulation Studies.*
14. *Al-Achi, A., Gupta, M. R., & Stagner, W. C. (2022). Integrated pharmaceutics: applied preformulation, product design, and regulatory science. John Wiley & Sons.*
15. *Bynum, K. C. (2011). Preformulation and early phase method development. In Separation Science and Technology (Vol. 10, pp. 361-396). Academic Press.*
16. *Kim, S. J., Lee, S. E., Ng, C. L., Lee, J. K., Kim, T. H., Cho, C. W., & Park, J. S. (2015). Preformulation and in vitro physicochemical characterization of fenofibrate-loaded emulsion. Journal of Pharmaceutical Investigation, 45, 669-674.*
17. *Steele, G. (2016). Preformulation as an aid to product design in early drug development. In Pharmaceutical preformulation and formulation (pp. 200-258). CRC Press.*
18. *Lima, S. G., Pinho, L. A., Pereira, M. N., Gratieri, T., Sa-Barreto, L. L., Gelfuso, G. M., & Cunha-Filho, M. (2018). Preformulation studies of finasteride to design matrix systems for topical delivery. Journal of pharmaceutical and biomedical analysis, 161, 273-279.*
19. *Górniak, A., Złocińska, A., Trojan, M., Pęcak, A., & Karolewicz, B. (2022). Preformulation studies of Ezetimibe-Simvastatin solid dispersions in the development of fixed-dose combinations. Pharmaceutics, 14(5), 912.*
20. *Teixeira, F. V., Alves, G. L., Ferreira, M. H., Taveira, S. F., da Cunha-Filho, M. S. S., & Marreto, R. N. (2018). Preformulation studies to guide the development of raloxifene lipid-based delivery systems. Journal of thermal analysis and calorimetry, 132, 365-371.*